Cargando…
Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts
Multiple myeloma osteolytic disease is caused by an uncoupled bone-remodelling process with an increased osteoclast activity. Disease development relies on interactions between myeloma cells and bone marrow stromal cells. Recent findings suggest a role for glycan-binding proteins in myeloma microenv...
Autores principales: | Muller, Joséphine, Duray, Elodie, Lejeune, Margaux, Dubois, Sophie, Plougonven, Erwan, Léonard, Angélique, Storti, Paola, Giuliani, Nicola, Cohen-Solal, Martine, Hempel, Ute, Thijssen, Victor L., Beguin, Yves, Heusschen, Roy, Caers, Jo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406775/ https://www.ncbi.nlm.nih.gov/pubmed/30813402 http://dx.doi.org/10.3390/cancers11020261 |
Ejemplares similares
-
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
por: Muller, Joséphine, et al.
Publicado: (2018) -
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
por: Heusschen, Roy, et al.
Publicado: (2016) -
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020) -
Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2021) -
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
por: Duray, Elodie, et al.
Publicado: (2021)